Ziv-aflibercept in macular disease

BACKGROUND/AIMS: Aflibercept is an approved therapy for neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DME). In vitro and in vivo studies did not detect toxicity to the retinal pigment epithelium cells using the approved cancer protein, ziv-aflibercept. Our purpose i...

Descripción completa

Detalles Bibliográficos
Autores principales: Mansour, Ahmad M, Al-Ghadban, Sara I, Yunis, Muhammad H, El-Sabban, Marwan E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518747/
https://www.ncbi.nlm.nih.gov/pubmed/25677668
http://dx.doi.org/10.1136/bjophthalmol-2014-306319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518747/
https://www.ncbi.nlm.nih.gov/pubmed/25677668
http://dx.doi.org/10.1136/bjophthalmol-2014-306319

Ejemplares similares